Lakewood-Amedex is set to highlight Nu-3 and its Bisphosphocin® antimicrobial platform during the Maxim Growth Summit, ThinkEquity Conference, and IDWeek.
Lakewood-Amedex Biotherapeutics, Inc. (NASDAQ:LABT)
SARASOTA, FL, UNITED STATES, October 2, 2026 /EINPresswire.com/ — Lakewood-Amedex Biotherapeutics, Inc. (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology enterprise advancing an innovative category of potent, rapid-acting, broad-spectrum antimicrobials for infectious diseases referred to as the Bisphosphocin® class, has announced that CEO Kelvin Cooper, Ph.D., is scheduled to take part in three forthcoming industry gatherings.
Lakewood-Amedex Biotherapeutics Inc. is a B2i Digital Featured Company. See the company's in-depth profile at: https://b2idigital.com/lakewood-amedex-biotherapeutics-inc-1
Dr. Cooper will be present at the Maxim Growth Summit on October 14, 2026, in New York City. He will additionally attend and deliver a presentation at the ThinkEquity Conference on October 15, 2026, in New York City. Later that month, Dr. Cooper will display a poster on Nu-3 preclinical findings at IDWeek on October 22, 2026, in Washington, D.C.
Specifics are provided below:
Event: Maxim Growth Summit
Date: October 13-14, 2026
Location: Hard Rock Hotel, New York City
Event: ThinkEquity Conference
Date: October 15, 2026
Location: The Mandarin Oriental Hotel, New York City
Presentation: Nu-3 – A Novel, Broad Spectrum Antimicrobial Compound with High In- Vitro Activity Against Resistant Pathogens for the Treatment of Infected Diabetic Foot Ulcers.
Presentation Time: 3:30 pm
Event: IDWeek
Date: October 21-24, 2026
Location: Walter E. Washington Convention Center, Washington, D.C. (Hybrid Format Available)
These conferences offer opportunities for Lakewood-Amedex to connect with members of the investment, biotechnology, and infectious disease sectors, as well as to showcase the Company's ongoing development initiatives involving the Bisphosphocin® antimicrobial platform.
About Lakewood-Amedex Biotherapeutics, Inc.
Lakewood-Amedex Biotherapeutics, Inc. (NASDAQ: LABT) is a clinical-stage biotechnology Company advancing a novel class of fast-acting, broad-spectrum antimicrobials – the Bisphosphocin® class – designed to address infectious diseases and mitigate the danger posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. For more information, please visit https://lakewoodamedex.com.
Contacts:
Investor Relations
Tiberend Strategic Advisors, Inc.
David Irish
(231) 632-0002
dirish@tiberend.com
Media Relations
Tiberend Strategic Advisors, Inc.
Casey McDonald
(646) 577-8520
cmcdonald@tiberend.com
Michelle Katsel
(201) 790-3390
mkatsel@tiberend.com
Additional Contact
David Shapiro
B2i Digital, Inc.
+1 212-579-4844
david@b2idigital.com
Visit us on social media:
LinkedIn
Instagram
Facebook
YouTube
TikTok
X
Other
Also worth a look: Mitolyn, Built Around the Purple Peel Exploit, has been Launched, Designed to Enhance Mitochondrial Health & Manage Weight and Out Today: “My Favorite Things” by Award-winning Vocalist Nicole Henry.
LABT CEO Kelvin Cooper heads to three October conferences, including Nu-3 presentations.
